Search
Dasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigational[A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] … BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigational[L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845] … [A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.
Calcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawnIts effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. … Calcium carbimide, sold as the citrate salt, is an alcohol-sensitizing agent.
Lornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. … Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties.
Products: LORİXAM 8 MG IM/IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 1 flakon+1 çözücü ampul ve 3 flakon+3 çözücü ampul, LORNOX 8 MG IM/IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETAgomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalIn 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. … Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor AntagonistsTinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalTinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa.
Products: INNOHEP 4500 IE 0.45ML, INNOHEP 8.000 IE/0.4MLMipomersen
go.drugbank.com/drugs/DB05528ApprovedIt is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. … Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.
Zomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnThe manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]
Ledipasvir
go.drugbank.com/drugs/DB09027ApprovedThis is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … Ledipasvir and other direct acting antivirals are very potent options for the treatment of Hepatitis C, as they exhibit a high barrier to the development of resistance [A19593].